About the Authors
- Linda Kwakkenbos
-
* E-mail: kwakkenbosL@gmail.com
Affiliations Department of Rheumatology, Sint Maartenskliniek Nijmegen, The Netherlands, Department of Psychiatry, McGill University, Montréal, Québec, Canada, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
- Erin Arthurs
-
Affiliations Department of Psychiatry, McGill University, Montréal, Québec, Canada, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
- Frank H. J. van den Hoogen
-
Affiliation Department of Rheumatology, Sint Maartenskliniek Nijmegen, The Netherlands
- Marie Hudson
-
Affiliations Department of Medicine (Division of Rheumatology), McGill University, Montréal, Québec, Canada, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
- Wim G. J. M. van Lankveld
-
Affiliation Department of Rheumatology, Sint Maartenskliniek Nijmegen, The Netherlands
- Murray Baron
-
Affiliations Department of Medicine (Division of Rheumatology), McGill University, Montréal, Québec, Canada, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
- Cornelia H. M. van den Ende
-
Affiliation Department of Rheumatology, Sint Maartenskliniek Nijmegen, The Netherlands
- Brett D. Thombs
-
Affiliations Department of Psychiatry, McGill University, Montréal, Québec, Canada, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada, Department of Medicine (Division of Rheumatology), McGill University, Montréal, Québec, Canada, Department of Educational and Counselling Psychology, McGill University, Montréal, Québec, Canada, School of Nursing, McGill University, Montréal, Québec, Canada, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
- for the Canadian Scleroderma Research Group
-
¶Members of the Canadian Scleroderma Research Group can be found in the acknowledgments.
Competing Interests
Actelion Pharmaceuticals and Pfizer Inc. have provided unrestricted educational and research funds to the Canadian Scleroderma Research Group. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: LK EA FH MH WL MB CE BDT. Performed the experiments: LK EA FH MH WL MB CE BDT. Analyzed the data: LK EA BDT. Contributed reagents/materials/analysis tools: FH MH WL MB CE. Wrote the paper: LK EA FH MH WL MB CE BDT.